Possible therapy for ALS based on the cyanobacteria/BMAA hypothesis

Walter G. Bradley

doi:10.3109/17482960903285951

Possible therapy for ALS based on the cyanobacteria/BMAA hypothesis

Walter G. Bradley

Neurology

Research output: Contribution to journal › Article

5 Scopus citations

Abstract

Although the cyanobacteria/BMAA hypothesis of the cause of ALS and other age-related neurodegenerative diseases remains to be proven, it is not too early to ask whether treatment would be possible if the hypothesis were correct. This paper reviews the possible ways that chronic BMAA neurotoxicity could be prevented or treated.

Original language	English (US)
Pages (from-to)	118-123
Number of pages	6
Journal	Amyotrophic Lateral Sclerosis
Volume	10
Issue number	SUPPL. 2
DOIs	https://doi.org/10.3109/17482960903285951
State	Published - Dec 1 2009

Keywords

Aminoacyl-tRNA synthetase
Amyotrophic lateral sclerosis (ALS)
Blood-brain barrier
BMAA
Therapeutic trial

ASJC Scopus subject areas

Clinical Neurology
Neurology

Access to Document

10.3109/17482960903285951

Fingerprint Dive into the research topics of 'Possible therapy for ALS based on the cyanobacteria/BMAA hypothesis'. Together they form a unique fingerprint.

Cite this

Bradley, W. G. (2009). Possible therapy for ALS based on the cyanobacteria/BMAA hypothesis. Amyotrophic Lateral Sclerosis, 10(SUPPL. 2), 118-123. https://doi.org/10.3109/17482960903285951

@article{2a6646a5394c4ce6bfc837cd3ceee7e6,

title = "Possible therapy for ALS based on the cyanobacteria/BMAA hypothesis",

abstract = "Although the cyanobacteria/BMAA hypothesis of the cause of ALS and other age-related neurodegenerative diseases remains to be proven, it is not too early to ask whether treatment would be possible if the hypothesis were correct. This paper reviews the possible ways that chronic BMAA neurotoxicity could be prevented or treated.",

keywords = "Aminoacyl-tRNA synthetase, Amyotrophic lateral sclerosis (ALS), Blood-brain barrier, BMAA, Therapeutic trial",

author = "Bradley, {Walter G.}",

year = "2009",

month = dec,

day = "1",

doi = "10.3109/17482960903285951",

language = "English (US)",

volume = "10",

pages = "118--123",

journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",

issn = "2167-8421",

publisher = "Informa Healthcare",

number = "SUPPL. 2",

}

TY - JOUR

T1 - Possible therapy for ALS based on the cyanobacteria/BMAA hypothesis

AU - Bradley, Walter G.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Although the cyanobacteria/BMAA hypothesis of the cause of ALS and other age-related neurodegenerative diseases remains to be proven, it is not too early to ask whether treatment would be possible if the hypothesis were correct. This paper reviews the possible ways that chronic BMAA neurotoxicity could be prevented or treated.

AB - Although the cyanobacteria/BMAA hypothesis of the cause of ALS and other age-related neurodegenerative diseases remains to be proven, it is not too early to ask whether treatment would be possible if the hypothesis were correct. This paper reviews the possible ways that chronic BMAA neurotoxicity could be prevented or treated.

KW - Aminoacyl-tRNA synthetase

KW - Amyotrophic lateral sclerosis (ALS)

KW - Blood-brain barrier

KW - BMAA

KW - Therapeutic trial

UR - http://www.scopus.com/inward/record.url?scp=74549148873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549148873&partnerID=8YFLogxK

U2 - 10.3109/17482960903285951

DO - 10.3109/17482960903285951

M3 - Article

C2 - 19929743

AN - SCOPUS:74549148873

VL - 10

SP - 118

EP - 123

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

IS - SUPPL. 2

ER -